Roth Mkm Begins Coverage on GT Biopharma (NASDAQ:GTBP)

Equities research analysts at Roth Mkm started coverage on shares of GT Biopharma (NASDAQ:GTBP) in a research note issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Roth Mkm’s target price would indicate a potential upside of 280.62% from the company’s current price.

GT Biopharma Stock Performance

GT Biopharma stock opened at $2.89 on Monday. GT Biopharma has a 12-month low of $1.92 and a 12-month high of $10.66. The firm has a 50-day moving average price of $2.68 and a 200-day moving average price of $2.73.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.